心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2014年
3期
315-317
,共3页
冠状动脉疾病%心绞痛%阿托伐他汀%辛伐他汀
冠狀動脈疾病%心絞痛%阿託伐他汀%辛伐他汀
관상동맥질병%심교통%아탁벌타정%신벌타정
Coronary artery disease%Angina pectoris%Atorvastatin%Simvastatin
目的：比较阿托伐他汀与辛伐他汀治疗冠心病心绞痛的疗效及安全性。方法：选择冠心病慢性稳定型心绞痛患者150例，按数字表法被随机均分成阿托伐他汀组和辛伐他汀组。比较治疗前后两组间心绞痛发作次数、持续时间、疼痛程度、硝酸甘油用量差异及血脂变化，随访6个月，统计心血管事件发生率差异。结果：与治疗前比较，治疗12周后两组患者的心绞痛发作次数与硝酸甘油用量明显减少，每次持续时间缩短，疼痛程度明显减轻（P 均＜0.05）；但两组间治疗前及治疗后上述指标比较均无统计学差异（P均＞0.05）。与治疗前相比，治疗后阿托伐他汀组和辛伐他汀组患者的血清总胆固醇[（5.62±0.54）mmol/L比（3.68±0.41）mmol/L，（5.78±0.56）mmol/L比（3.33±0.43）mmol/L]、甘油三酯[（2.30±0.42）mmol/L比（1.62±0.34）mmol/L，（2.35±0.41）mmol/L比（1.68±0.69）mmol/L]、低密度脂蛋白胆固醇[（3.56±1.22）mmol/L比（2.76±0.83）mmol/L，（3.48±1.21）mmol/L比（2.43±0.72）mmol/L]显著下降，高密度脂蛋白胆固醇[（1.32±0.35）mmol/L比（1.58±0.34）mmol/L，（1.30±0.46）mmol/L比（1.60±0.45）mmol/L]水平则显著上升（P均＜0.05），治疗后两组间血脂水平无明显差异（P＞0.05）；随访期间两组间心血管事件发生率无明显差异（28.00％比25.33％，P＞0.05）。结论：阿托伐他汀与辛伐他汀均能有效调节高血脂状态，治疗冠心病心绞痛疗效好，安全性高。
目的：比較阿託伐他汀與辛伐他汀治療冠心病心絞痛的療效及安全性。方法：選擇冠心病慢性穩定型心絞痛患者150例，按數字錶法被隨機均分成阿託伐他汀組和辛伐他汀組。比較治療前後兩組間心絞痛髮作次數、持續時間、疼痛程度、硝痠甘油用量差異及血脂變化，隨訪6箇月，統計心血管事件髮生率差異。結果：與治療前比較，治療12週後兩組患者的心絞痛髮作次數與硝痠甘油用量明顯減少，每次持續時間縮短，疼痛程度明顯減輕（P 均＜0.05）；但兩組間治療前及治療後上述指標比較均無統計學差異（P均＞0.05）。與治療前相比，治療後阿託伐他汀組和辛伐他汀組患者的血清總膽固醇[（5.62±0.54）mmol/L比（3.68±0.41）mmol/L，（5.78±0.56）mmol/L比（3.33±0.43）mmol/L]、甘油三酯[（2.30±0.42）mmol/L比（1.62±0.34）mmol/L，（2.35±0.41）mmol/L比（1.68±0.69）mmol/L]、低密度脂蛋白膽固醇[（3.56±1.22）mmol/L比（2.76±0.83）mmol/L，（3.48±1.21）mmol/L比（2.43±0.72）mmol/L]顯著下降，高密度脂蛋白膽固醇[（1.32±0.35）mmol/L比（1.58±0.34）mmol/L，（1.30±0.46）mmol/L比（1.60±0.45）mmol/L]水平則顯著上升（P均＜0.05），治療後兩組間血脂水平無明顯差異（P＞0.05）；隨訪期間兩組間心血管事件髮生率無明顯差異（28.00％比25.33％，P＞0.05）。結論：阿託伐他汀與辛伐他汀均能有效調節高血脂狀態，治療冠心病心絞痛療效好，安全性高。
목적：비교아탁벌타정여신벌타정치료관심병심교통적료효급안전성。방법：선택관심병만성은정형심교통환자150례，안수자표법피수궤균분성아탁벌타정조화신벌타정조。비교치료전후량조간심교통발작차수、지속시간、동통정도、초산감유용량차이급혈지변화，수방6개월，통계심혈관사건발생솔차이。결과：여치료전비교，치료12주후량조환자적심교통발작차수여초산감유용량명현감소，매차지속시간축단，동통정도명현감경（P 균＜0.05）；단량조간치료전급치료후상술지표비교균무통계학차이（P균＞0.05）。여치료전상비，치료후아탁벌타정조화신벌타정조환자적혈청총담고순[（5.62±0.54）mmol/L비（3.68±0.41）mmol/L，（5.78±0.56）mmol/L비（3.33±0.43）mmol/L]、감유삼지[（2.30±0.42）mmol/L비（1.62±0.34）mmol/L，（2.35±0.41）mmol/L비（1.68±0.69）mmol/L]、저밀도지단백담고순[（3.56±1.22）mmol/L비（2.76±0.83）mmol/L，（3.48±1.21）mmol/L비（2.43±0.72）mmol/L]현저하강，고밀도지단백담고순[（1.32±0.35）mmol/L비（1.58±0.34）mmol/L，（1.30±0.46）mmol/L비（1.60±0.45）mmol/L]수평칙현저상승（P균＜0.05），치료후량조간혈지수평무명현차이（P＞0.05）；수방기간량조간심혈관사건발생솔무명현차이（28.00％비25.33％，P＞0.05）。결론：아탁벌타정여신벌타정균능유효조절고혈지상태，치료관심병심교통료효호，안전성고。
Objective:To compare therapeutic effect and safety between atorvastatin and simvastatin treating angina pectoris of coronary heart disease (CHD).Methods:A total of 150 patients with chronic stable angina pectoris (SAP)of CHD were selected and randomly and equally divided into atorvastatin group and simvastatin group accord-ing to number table method.Changes of angina pectoris attack frequency,duration,degree of pain,nitroglycerin dosage and blood lipids were compared between two groups before and after treatment.All patients were followed up six months.Results:Compared with before treatment,there were significant reductions in angina pectoris attack frequency,duration,pain degree and nitroglycerin dosage after treatment 12 weeks in two groups,P<0.05 all;but there were no significant difference in above indexes between two groups before and after treatment (P>0.05 all). Compared with before treatment,there were significant reductions in serum levels of total cholesterol [ (5.62 ± 0.54)mmol/L vs.(3.68±0.41)mmol/L,(5.78±0.56)mmol/L vs.(3.33±0.43)mmol/L],triglyceride [(2.30 ±0.42)mmol/L vs.(1.62±0.34)mmol/L,(2.35±0.41)mmol/L vs.(1.68±0.69)mmol/L]and low density lipoprotein cholesterol [(3.56±1.22)mmol/L vs.(2.76±0.83)mmol/L,(3.48±1.21)mmol/L vs.(2.43± 0.72)mmol/L],and significant increase in level of high density lipoprotein cholesterol [(1.32±0.35)mmol/L vs. (1.58±0.34)mmol/L,(1.30±0.46)mmol/L vs.(1.60±0.45)mmol/L]in atorvastatin group and simvastatin group after treatment (P<0.05 all),but there were no significant difference in blood lipid levels between two groups after treatment (P>0.05);there was no significant difference in incidence rate of cardiovascular events (28.00% vs.25.33%,P>0.05)between two groups during follow-up.Conclusion:Both atorvastatin and simvasta-tin can effectively regulate the state of high blood lipid,and possess good effect and safety for angina pectoris of coronary heart disease.
